Fitzgerald Kevin Joseph

CSO & EVP, Head of ResearchALNYLAM PHARMACEUTICALS, INC. (ALNY) · full profile →Form 4 · filed Mar 6, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$418K
Net Open-Market Flow
-$418K
Transactions
12
12 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 5, 2026Sell(S)148$324.60$48K21K
Mar 5, 2026Sell(S)153$326.24$50K21K
Mar 5, 2026Sell(S)233$323.25$75K21K
Mar 5, 2026Sell(S)124$321.81$40K21K
Mar 4, 2026Sell(S)75$324.88$24K21K
Mar 4, 2026Sell(S)57$325.67$19K21K
Mar 4, 2026Sell(S)28$320.01$9K22K
Mar 4, 2026Sell(S)79$321.82$25K22K
Mar 4, 2026Sell(S)59$320.81$19K22K
Mar 4, 2026Sell(S)29$319.03$9K22K
Mar 4, 2026Sell(S)96$323.01$31K22K
Mar 4, 2026Sell(S)210$323.84$68K21K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001735276-26-000059) within minutes of acceptance. Every field above traces to the original document. Verify it directly: